Kodiak Sciences Inc. (KOD) Surges to All Time High, Is Now Top Performer

The stock of Kodiak Sciences Inc. (NASDAQ:KOD) reached all time high today, Sep, 13 and still has $15.46 target or 4.00 % above today’s $14.87 share price. This indicates more upside for the $562.94M company. This technical setup was reported by Barchart.com. If the $15.46 PT is reached, the company will be worth $22.52M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 5.84% or $0.82 during the last trading session, reaching $14.87. About 186,084 shares traded or 9.55% up from the average. Kodiak Sciences Inc. (NASDAQ:KOD) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Analysts await Kodiak Sciences Inc. (NASDAQ:KOD) to report earnings on November, 15. They expect $-0.33 EPS, up 75.19 % or $1.00 from last year’s $-1.33 per share. After $-0.31 actual EPS reported by Kodiak Sciences Inc. for the previous quarter, Wall Street now forecasts 6.45 % negative EPS growth.

More notable recent Kodiak Sciences Inc. (NASDAQ:KOD) news were published by: Prnewswire.com which released: “Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference – PRNewswire” on May 30, 2019, also Benzinga.com with their article: “The Week Ahead In Biotech: Pharma Earnings Pick Up Pace – Benzinga” published on July 20, 2019, Seekingalpha.com published: “Kodiak Sciences launches IPO – Seeking Alpha” on September 24, 2018. More interesting news about Kodiak Sciences Inc. (NASDAQ:KOD) were released by: Finance.Yahoo.com and their article: “Eastman Kodak Closes the Sale of $100 Million of Convertible Notes – Yahoo Finance” published on May 24, 2019 as well as Seekingalpha.com‘s news article titled: “Stocks To Watch: Automakers, Macau Names And CinemaCon Action – Seeking Alpha” with publication date: March 30, 2019.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company has market cap of $562.94 million. The company's lead product candidate is KSI-301, a vascular endothelial growth factor -biological agent that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. It currently has negative earnings. The Company’s preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.